(Date:11/30/2009)...alif., Nov. 30 BioMarin ...ay that the Food and Drug Administration (FDA) has...ridine (3,4-DAP), amifampridine phosphate, for the...Syndrome (LEMS). 3,4-DAP has previously received ...ber 2009, the Committee for Medicinal Products for...
(Date:11/30/2009)... and COPENHAGEN, Nov. 30 Exiqon A/...hat the Harvard Medical School ICCB-Longwood Scree...croRNA Screening Center of Excellence. ICCB-L sup... associated hospitals and institutions, for high-t...raries. ,, MicroRNAs are a novel class of small...
(Date:11/30/2009)... , AMSTERDAM, November 30 /PRNew...publisher of scientific, medical and technical pro...nch of Embase, its comprehensive biomedical,databa...m more than 7,000,active, peer reviewed journals. ...e advancement of new biomedical,and pharmaceutical...
(Date:11/27/2009)...RHAM, N.C., Nov. 27 Cromoz Inc., l...ter-soluble carbon nanotube-based cancer drug deli... carbon nanotubes, which have functional groups on... drugs, was developed in partnership with the Indi...n nanotubes serves as a drug delivery vehicle with...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2